CytoDyn will submit the revised protocol for CD16
Post# of 148292
(Total Views: 651)
Posted On: 01/30/2022 11:38:57 PM
CytoDyn will submit the revised protocol for CD16 providing for a reduction in total enrollment from 330 to 126 patients, with interim efficacy analysis by DSMB after 40% of patients (51 patients) are enrolled and have completed follow-up to Day 28.
Taken from 12/08/21 PR
I recall the cd-17 trial cutting total enrollment in about half to 300 i can’t find on PR maybe mentioned on proactive
Taken from 12/08/21 PR
I recall the cd-17 trial cutting total enrollment in about half to 300 i can’t find on PR maybe mentioned on proactive
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼